US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.02 against a street estimate of -0.04 — a beat of 50.0%.
Analysts rate Canopy Growth Corp a buy (2 buy, 6 hold, 0 sell out of 8) with an average price target of $1.20.
| Fund | Stake |
|---|---|
| Tidal Investments LLC. | 2.17% |
| Morgan Stanley - Brokerage Accounts | 0.46% |
| Lazard Asset Management LLC | 0.44% |
| Jane Street Group LLC | 0.37% |
| UBS Group AG | 0.33% |
| The Goldman Sachs Group Inc | 0.31% |
| Susquehanna International Group, LLP | 0.29% |
| Royal Bank of Canada | 0.26% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Canopy Growth Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.